Medicare GLP-1 Coverage: The 2027 Changes Explained
The White House-negotiated Medicare prices for Ozempic and Wegovy take effect January 1, 2027. For Medicare beneficiaries, this is the most significant GLP-1 access change in years. Here's what to expect.
The Verdict
Starting January 1, 2027: Medicare Part D pays approximately 71% less for Ozempic and Wegovy. Beneficiary copays drop dramatically. Coverage expands to more Medicare patients. The commercial insurance market will feel downstream pressure by 2028. If you're a Medicare beneficiary, delaying GLP-1 start until 2027 may save thousands if clinically reasonable.
In late 2025, the White House announced negotiated Medicare prices for Ozempic and Wegovy under the Inflation Reduction Act drug-pricing provisions. The negotiated prices represent roughly a 71% reduction from previous Medicare pricing and take effect January 1, 2027. For Medicare beneficiaries, this is transformative. For the broader GLP-1 market, it's the beginning of a structural price shift.
What was negotiated
- Ozempic: 71% price reduction for Medicare Part D.
- Wegovy: 71% price reduction for Medicare Part D (where covered).
- Effective date: January 1, 2027.
- Applies to: Medicare beneficiaries using Part D for covered indications.
The specific discount of 71% is notable — this is the maximum negotiated amount allowable under current IRA rules for these medications. Both Novo Nordisk and Eli Lilly resisted the negotiations but ultimately agreed rather than face penalties.
What this means for Medicare beneficiaries
T2D patients on Medicare Part D
If you're currently covered for Ozempic under Part D for T2D indication, your copay will likely drop significantly in 2027. Beyond copay changes, more Part D plans are likely to add Ozempic to preferred formulary tiers once the government-negotiated price applies.
Medicare beneficiaries with weight-loss indication
Wegovy coverage under Medicare has been historically limited by the statutory exclusion of weight-loss medications. The 2024 cardiovascular risk reduction approval for Wegovy opened a coverage pathway for patients with established CVD. The 2027 negotiated pricing makes this pathway economically more viable for plans to offer.
Expected outcomes:
- More Part D plans will add Wegovy coverage for CV risk indication
- Copays will drop for already-covered beneficiaries
- Prior authorization requirements may remain strict to control utilization
Beneficiaries currently paying cash
Medicare beneficiaries who've been self-paying for GLP-1s (often at NovoCare's $349/mo rate for Wegovy) will have new options through Part D coverage starting 2027. The transition may require formulary research, prior authorization, and switching prescription channels.
What remains unchanged
- Mounjaro and Zepbound: These are Lilly products and were not part of the initial Medicare negotiation round. Negotiated prices for tirzepatide products are expected in future negotiation cycles (possibly 2028 or 2029).
- Medicare Advantage plans: May implement changes differently than traditional Medicare Part D. Check specific plan details.
- Medicare statutory weight-loss exclusion: Not fully repealed. Weight-loss indication remains excluded except through narrow pathways (CV risk reduction).
- Medicare Part B coverage: Not affected by Part D negotiations.
Timeline and strategy
| Timeframe | What to Expect |
|---|---|
| Now through Dec 2026 | Medicare pricing unchanged. Beneficiaries continue with current coverage, pricing, and prior auth rules. Consider whether delaying start until 2027 is clinically reasonable. |
| Late 2026 | Part D plans announce 2027 formularies. Look for expanded Wegovy and reduced-copay Ozempic in 2027 coverage options. Open enrollment selections matter. |
| January 2027 | Negotiated prices take effect. Reduced copays for beneficiaries. Start new coverage as appropriate. |
| Throughout 2027 | Commercial insurance plans begin adjusting pricing in response to Medicare shifts. Expect gradual cash-price pressure. |
| 2028+ | Next negotiation cycles may affect Mounjaro/Zepbound. Broader market pricing continues to adjust. |
Should you delay starting until 2027?
For Medicare beneficiaries currently cash-paying or facing high copays, the question is whether to wait until January 2027 for the reduced prices. Considerations:
Reasons to start now rather than wait
- Medical necessity. If your T2D is poorly controlled or your obesity-related conditions are progressing, don't delay medically necessary treatment.
- Cardiovascular risk. Wegovy's CV benefit shouldn't be delayed if your risk profile warrants it.
- Current savings pathways exist. Manufacturer assistance, community pharmacy programs, or clinical trials may already offer affordable access.
Reasons to delay if clinically reasonable
- Significant monthly savings. 71% price reduction is substantial over a multi-year treatment period.
- Better coverage options. Part D plans will compete for customers with expanded GLP-1 benefits in 2027.
- Lower out-of-pocket exposure. Copays and deductibles both likely improve.
Discuss with your provider whether delaying 6–12 months poses clinical risk. For stable T2D without obesity-related complications, delay may be reasonable. For active cardiovascular risk or uncontrolled diabetes, delay isn't advised.
Commercial insurance implications
Medicare pricing changes historically influence commercial insurance negotiations with a 1–2 year lag. Expect:
- 2027–2028: Commercial carriers negotiate new pricing with manufacturers using Medicare rates as reference.
- 2028–2029: Cash-pay prices from manufacturers may decrease further as commercial pressure builds.
- Long-term: The entire GLP-1 market likely settles at meaningfully lower prices by late 2028.
For commercially insured patients in 2026, this is context for long-term planning but doesn't change immediate decisions. Your 2026 coverage is what it is.
Potential complications
- Formulary coverage decisions. Individual Part D plans still choose which GLP-1s to cover and at what tier.
- Prior authorization requirements. Expected to remain strict even with lower prices.
- Supply chain pressure. Increased Medicare demand could strain manufacturing if capacity isn't scaled.
- Manufacturer response. Novo and Lilly may adjust other programs (savings cards, subscriptions) in response to Medicare changes.
- Legal challenges. Some manufacturers have filed legal challenges to the IRA drug-pricing provisions; current litigation status affects implementation timeline.
For beneficiaries on compounded GLP-1s
Medicare beneficiaries currently using compounded semaglutide or tirzepatide through cash-pay telehealth may want to reassess in 2027. If Part D coverage for brand-name Ozempic or Wegovy becomes available at reasonable copay, the clinical and regulatory advantages of FDA-approved medication make it generally preferable to compounded alternatives.
The calculation for Medicare beneficiaries in 2027:
- Compounded semaglutide: $146–249/month cash-pay
- Brand-name Ozempic with 2027 Medicare: Potentially $20–75/month copay
- Coverage for Wegovy (if CV indication): Similar copay range
For most Medicare beneficiaries, the brand-name path becomes clearly superior in 2027 if coverage is available.
Bottom line
The 2027 Medicare negotiated prices for Ozempic and Wegovy represent a meaningful shift in GLP-1 access for Medicare beneficiaries. A 71% price reduction plus expected coverage expansion changes the affordability calculation substantially. For beneficiaries currently cash-paying or facing high copays, planning for 2027 transitions makes sense. For commercial patients, the 2027 change signals where market pricing is heading — relief may come, but with a 1–2 year lag.